Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.55
ATRC's Cash to Debt is ranked higher than
57% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. ATRC: 3.55 )
Ranked among companies with meaningful Cash to Debt only.
ATRC' s Cash to Debt Range Over the Past 10 Years
Min: 1.42  Med: 14.71 Max: No Debt
Current: 3.55
Equity to Asset 0.76
ATRC's Equity to Asset is ranked higher than
73% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. ATRC: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
ATRC' s Equity to Asset Range Over the Past 10 Years
Min: -2.52  Med: 0.67 Max: 0.87
Current: 0.76
-2.52
0.87
F-Score: 4
Z-Score: 7.75
M-Score: -2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -16.92
ATRC's Operating margin (%) is ranked lower than
74% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. ATRC: -16.92 )
Ranked among companies with meaningful Operating margin (%) only.
ATRC' s Operating margin (%) Range Over the Past 10 Years
Min: -38.62  Med: -17.57 Max: -5.41
Current: -16.92
-38.62
-5.41
Net-margin (%) -17.55
ATRC's Net-margin (%) is ranked lower than
72% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. ATRC: -17.55 )
Ranked among companies with meaningful Net-margin (%) only.
ATRC' s Net-margin (%) Range Over the Past 10 Years
Min: -40.97  Med: -16.75 Max: -6.43
Current: -17.55
-40.97
-6.43
ROE (%) -16.64
ATRC's ROE (%) is ranked lower than
73% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. ATRC: -16.64 )
Ranked among companies with meaningful ROE (%) only.
ATRC' s ROE (%) Range Over the Past 10 Years
Min: -160.02  Med: -33.68 Max: -15.8
Current: -16.64
-160.02
-15.8
ROA (%) -13.63
ATRC's ROA (%) is ranked lower than
72% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. ATRC: -13.63 )
Ranked among companies with meaningful ROA (%) only.
ATRC' s ROA (%) Range Over the Past 10 Years
Min: -42.11  Med: -22.73 Max: -11.04
Current: -13.63
-42.11
-11.04
ROC (Joel Greenblatt) (%) -71.48
ATRC's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.36 vs. ATRC: -71.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATRC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -220.3  Med: -115.07 Max: -30.62
Current: -71.48
-220.3
-30.62
Revenue Growth (3Y)(%) -0.30
ATRC's Revenue Growth (3Y)(%) is ranked lower than
66% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ATRC: -0.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATRC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.9  Med: 1.90 Max: 915.8
Current: -0.3
-29.9
915.8
EBITDA Growth (3Y)(%) 35.20
ATRC's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. ATRC: 35.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATRC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.7  Med: -23.50 Max: 120.7
Current: 35.2
-62.7
120.7
EPS Growth (3Y)(%) 20.90
ATRC's EPS Growth (3Y)(%) is ranked higher than
76% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. ATRC: 20.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATRC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.4  Med: -25.70 Max: 36.4
Current: 20.9
-45.4
36.4
» ATRC's 10-Y Financials

Financials (Next Earnings Date: 2016-02-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ATRC Guru Trades in Q1 2015

Chuck Royce 363,000 sh (New)
RS Investment Management 1,174,830 sh (+11.44%)
» More
Q2 2015

ATRC Guru Trades in Q2 2015

RS Investment Management 1,710,210 sh (+45.57%)
Chuck Royce 404,000 sh (+11.29%)
» More
Q3 2015

ATRC Guru Trades in Q3 2015

Jim Simons 18,500 sh (New)
RS Investment Management 2,213,351 sh (+29.42%)
Chuck Royce 446,000 sh (+10.40%)
» More
Q4 2015

ATRC Guru Trades in Q4 2015

Jim Simons Sold Out
Chuck Royce 425,200 sh (-4.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ATRC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.72
ATRC's P/B is ranked lower than
74% of the 254 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.35 vs. ATRC: 3.72 )
Ranked among companies with meaningful P/B only.
ATRC' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 4.74 Max: 14.1
Current: 3.72
0.64
14.1
P/S 3.58
ATRC's P/S is ranked lower than
81% of the 256 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.83 vs. ATRC: 3.58 )
Ranked among companies with meaningful P/S only.
ATRC' s P/S Range Over the Past 10 Years
Min: 0.27  Med: 2.55 Max: 6.36
Current: 3.58
0.27
6.36
Current Ratio 2.15
ATRC's Current Ratio is ranked lower than
60% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. ATRC: 2.15 )
Ranked among companies with meaningful Current Ratio only.
ATRC' s Current Ratio Range Over the Past 10 Years
Min: 1.43  Med: 3.23 Max: 7.58
Current: 2.15
1.43
7.58
Quick Ratio 1.73
ATRC's Quick Ratio is ranked higher than
53% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. ATRC: 1.73 )
Ranked among companies with meaningful Quick Ratio only.
ATRC' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.62 Max: 7.18
Current: 1.73
1.14
7.18
Days Inventory 157.19
ATRC's Days Inventory is ranked lower than
62% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.52 vs. ATRC: 157.19 )
Ranked among companies with meaningful Days Inventory only.
ATRC' s Days Inventory Range Over the Past 10 Years
Min: 72.98  Med: 136.53 Max: 160.74
Current: 157.19
72.98
160.74
Days Sales Outstanding 49.26
ATRC's Days Sales Outstanding is ranked higher than
72% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 64.05 vs. ATRC: 49.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.02  Med: 55.84 Max: 62.63
Current: 49.26
43.02
62.63
Days Payable 114.70
ATRC's Days Payable is ranked higher than
82% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. ATRC: 114.70 )
Ranked among companies with meaningful Days Payable only.
ATRC' s Days Payable Range Over the Past 10 Years
Min: 56.31  Med: 106.78 Max: 167.47
Current: 114.7
56.31
167.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 56.34
ATRC's Price/Net Cash is ranked higher than
51% of the 70 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.09 vs. ATRC: 56.34 )
Ranked among companies with meaningful Price/Net Cash only.
ATRC' s Price/Net Cash Range Over the Past 10 Years
Min: 4.55  Med: 11.87 Max: 75.55
Current: 56.34
4.55
75.55
Price/Net Current Asset Value 10.61
ATRC's Price/Net Current Asset Value is ranked lower than
54% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.32 vs. ATRC: 10.61 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATRC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.03  Med: 7.71 Max: 32.77
Current: 10.61
1.03
32.77
Price/Tangible Book 5.65
ATRC's Price/Tangible Book is ranked lower than
65% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.96 vs. ATRC: 5.65 )
Ranked among companies with meaningful Price/Tangible Book only.
ATRC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.85  Med: 5.93 Max: 16.1
Current: 5.65
0.85
16.1
Price/Median PS Value 1.42
ATRC's Price/Median PS Value is ranked lower than
75% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.23 vs. ATRC: 1.42 )
Ranked among companies with meaningful Price/Median PS Value only.
ATRC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.98 Max: 2.22
Current: 1.42
0.13
2.22
Earnings Yield (Greenblatt) (%) -4.49
ATRC's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. ATRC: -4.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATRC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.52  Med: 0.00 Max: 0
Current: -4.49
-4.52
0

More Statistics

Revenue(Mil) $123
EPS $ -0.79
Beta0.83
Short Percentage of Float9.03%
52-Week Range $15.86 - 28.15
Shares Outstanding(Mil)32.22

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 130 159 181 221
EPS($) -0.94 -1.07 -0.93 -0.67
EPS without NRI($) -0.94 -1.07 -0.93 -0.67

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:A5I.Germany,
AtriCure Inc was incorporated in the State of Delaware as AtriCure, Inc. on October 31, 2000. It is a medical device company and engaged in developing, manufacturing and selling cardiac surgical ablation systems designed to create precise lesions, in cardiac, or heart, tissue for the treatment of atrial fibrillation, and systems for the exclusion of the left atrial appendage. It has two primary product lines for the ablation of cardiac tissue. Its primary product line for the ablation of cardiac tissue is the AtriCure Synergy Ablation System ('Synergy System'), a bipolar ablation clamp system and related radiofrequency ('RF') ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. Additionally, the Company offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System ('AtriClip System'), which is designed to safely and effectively exclude the left atrial appendage. Its products are utilized by cardiothoracic surgeons during concomitant open-heart surgical procedures and also during sole-therapy minimally invasive cardiac ablation procedures. During a concomitant open procedure, the surgeon ablates cardiac tissue and/or excludes the left atrial appendage, secondary, or concomitant, to a primary cardiac procedure such as a valve or coronary bypass. Additionally, cardiothoracic surgeons have adopted its products as a treatment alternative for AF patients who may be candidates for sole-therapy minimally invasive surgical procedures. Its Synergy System, which includes its Isolator Synergy clamps, a radiofrequency generator and related switchbox, is cleared by the FDA, for the treatment of patients with persistent and long-standing persistent AF during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures. In the United States it primarily sells its products to medical centers through its direct sales force. AtriCure Europe, B.V., its wholly-owned subsidiary incorporated and based in the Netherlands, markets and sells its products throughout Europe, the Middle East and Africa, or EMEA, primarily through distributors, while in certain markets, such as Germany and the Benelux region, it sell directly to medical centers. Additionally, it sells its products to other international distributors, mainly in Asia, South America and Canada. The Company's competitors include Biosense Webster, Inc. (a subsidiary of Johnson & Johnson), St. Jude Medical, Inc., and Medtronic, Inc. Its products are medical devices and are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries.
» More Articles for ATRC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
AtriCure Inc. (ATRC) President and CEO and Director David J Drachman sells 40,671 Shares Feb 25 2011 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2010 
AtriCure Inc. Reports Operating Results (10-Q) Nov 09 2009 
AtriCure Inc. Reports Operating Results (10-Q) Aug 10 2009 
AtriCure Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
ATRICURE, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Feb 08 2016
AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results Feb 01 2016
AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results Feb 01 2016
AtriCure to Present at the Leerink Global Healthcare Conference Jan 21 2016
AtriCure to Present at the Leerink Global Healthcare Conference Jan 21 2016
These stocks are beating the market despite massive selloff on Wall Street Jan 20 2016
AtriCure Announces Approval for the AtriClip in Japan Jan 19 2016
AtriCure Announces Approval for the AtriClip in Japan Jan 19 2016
AtriCure Announces Approval for the AtriClip in Japan Jan 19 2016
Hercules Announces Q4 Portfolio Update and Select Achievements fo ... Jan 12 2016
AtriCure eyes further expansion after 20% growth in 2015 Jan 11 2016
AtriCure posts 20 percent growth in 2015, eyes bigger growth ahead Jan 11 2016
AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2015 Updates 2016 Guidance Jan 11 2016
ATRICURE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 11 2016
AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2015 Updates 2016 Guidance Jan 11 2016
AtriCure, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016
AtriCure Announces the First Patient Enrolled in International Afib Study Dec 17 2015
AtriCure Announces the First Patient Enrolled in International Afib Study Dec 17 2015
ATRICURE, INC. Financials Dec 08 2015
What Do Hedge Funds Think of AtriCure Inc. (ATRC)? Nov 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK